This is a routine update on an established product. Traders should compare these sales figures to prior quarters and analyst expectations to assess the performance of Genmab's royalty stream, but no immediate trading action is warranted based on this announcement alone.
Price Chart
Executive Summary
Genmab announced Q1 2026 worldwide net sales of DARZALEX (daratumumab) at $3.964 billion, with $2.208 billion in the U.S. and $1.756 billion internationally. Genmab receives royalties on these sales under its license agreement with Johnson & Johnson. This is a routine quarterly sales update for a key product in Genmab's portfolio.
Key Facts
- Q1 2026 worldwide net sales of DARZALEX totaled $3,964 million
- $2,208 million of sales were in the U.S.
- $1,756 million of sales were in the rest of the world
- Genmab receives royalties on worldwide net sales from Johnson & Johnson
- This is a standard quarterly sales update, not a new event
Financial Impact
Royalty revenue based on $3.964 billion in Q1 2026 DARZALEX sales
Risk Factors
- Sales figures are reported by Johnson & Johnson, not Genmab, so actual royalty revenue may vary based on contract terms
- Market may have already priced in these sales expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000059 |
| Document: gmab_20260414x6k.htm | 0001434265-26-000059 |
| Document: 0001434265-26-000059-index-headers.html | 0001434265-26-000059 |
| Document: 0001434265-26-000059-index.html | 0001434265-26-000059 |
| Document: 0001434265-26-000059.txt | 0001434265-26-000059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 29, 2026 21w ago | 6-K | $251.55 $262.00 | ▲ +4.15% | ▲ +5.45% | $439.05 (+74.54%) |
May 13, 2026 23w ago | 6-K | $268.24 $249.00 | ▼ −7.17% | ▼ −6.56% | $439.05 (+63.68%) |
May 12, 2026 24w ago | 6-K | $264.64 $249.00 | ▼ −5.91% | ▼ −4.18% | $439.05 (+65.90%) |
May 8, 2026 24w ago | 6-K | $259.60 $249.00 | ▼ −4.08% | ▼ −3.78% | $439.05 (+69.13%) |
Apr 17, 2026 27w ago | 6-K | $281.75 $265.27 | ▼ −5.85% | ▼ −11.22% | $439.05 (+55.83%) |
Apr 17, 2026 27w ago | 6-K | $281.75 $265.27 | ▼ −5.85% | ▼ −11.22% | $439.05 (+55.83%) |
Apr 14, 2026 28w ago | 6-K | $273.25 $259.60 | ▼ −5.00% | ▼ −11.29% | $439.05 (+60.68%) |
Apr 1, 2026 29w ago | 6-K | $265.00 $255.25 | ▼ −3.68% | ▼ −13.40% | $439.05 (+65.68%) |
Apr 1, 2026 29w ago | 6-K | $265.00 $255.25 | ▼ −3.68% | ▼ −13.40% | $439.05 (+65.68%) |
Mar 30, 2026 30w ago | 6-K | $265.00 $255.25 | ▼ −3.68% | ▼ −13.10% | $439.05 (+65.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers